Northern Trust’s Metagenomi Therapeutics MGX Stock Holding History

Northern Trust’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$82K	Sell	68,938 -6,234	-8%	-$8.34K	﹤0.01%	4170
2026 Q1	$101K	Hold	75,172	–	–	﹤0.01%	4107
2025 Q4	$122K	Buy	75,172 +35,198	+88%	+$76.2K	﹤0.01%	4096
2025 Q3	$94.7K	Sell	39,974 -21,858	-35%	-$44.4K	﹤0.01%	4152
2025 Q2	$91.5K	Sell	61,832 -156,718	-72%	-$245K	﹤0.01%	4130
2025 Q1	$297K	Sell	218,550 -5,384	-2%	-$12.8K	﹤0.01%	3794
2024 Q4	$808K	Buy	223,934 +145,536	+186%	+$351K	﹤0.01%	3477
2024 Q3	$170K	Buy	78,398 +64,802	+477%	+$225K	﹤0.01%	3927
2024 Q2	$55.5K	Buy	13,596 +543	+4%	+$3.73K	﹤0.01%	4191
2024 Q1	$138K	Buy	+13,053	New	+$150K	﹤0.01%	3997

Other funds holding MGX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust's MGX Position: Q2 2026 in Review

Northern Trust reduced its Metagenomi Therapeutics (MGX) stake by 8.3% in Q2 2026, selling an estimated $8.34K and leaving 68,938 shares worth $82K. The position accounts for ﹤0.01% of the portfolio, ranked #4170.

Northern Trust first reported a position in MGX in Q1 2024 and has held it in 10 quarters since. The position peaked at $808K in Q4 2024. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

Northern Trust held 68,938 shares of Metagenomi Therapeutics worth $82K as of Q2 2026.
Northern Trust sold 6,234 Metagenomi Therapeutics shares in Q2 2026, an estimated $8.34K.
Metagenomi Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #4170 holding.
Northern Trust first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 10 quarters since.
Northern Trust's Metagenomi Therapeutics position peaked at $808K in Q4 2024.
43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.